Cogprints

The combinational effect of cardiac and biochemical markers in diabetic patients with cardiovascular disease

Palanisamy Pasupathi, YY Rao, Farook J, Sathiyamoorthy Subramaniyam, Babu Shankar Ponnusha, Athimoolam Ambika, Int J Cur Bio Med Sci. (2011) The combinational effect of cardiac and biochemical markers in diabetic patients with cardiovascular disease. [Journal (Paginated)]

Full text available as:

[img]
Preview
PDF (The combinational effect of cardiac and biochemical markers in diabetic patients with cardiovascular disease) - Published Version
Available under License Creative Commons Attribution No Derivatives.

528Kb

Abstract

Background: Clinicopathological correlations, as well as several angiographic studies, suggest that diabetic patients have more extensive atherosclerotic disease, affecting the coronary arteries in particular. We sought to examine the combinational effect of cardiac and biochemical markers in diabetic patients with cardiovascular disease. Method: The study population constituted 50 healthy subjects, 50 cardiovascular subjects with diabetes and 50 cardiovascular subjects without diabetes. The population was subjected to biochemical and cardiac marker analysis and the results were verified. Results and discussion: Studies suggest that glycated hemoglobin values in the abnormal range can identify persons at increased risk for coronary heart disease, stroke, and death before the diagnosis of diabetes, indicating that glycated hemoglobin is a useful marker of cardiovascular risk and death from any cause.

Item Type:Journal (Paginated)
Keywords:Atherosclerosis, glycated haemoglobin, cardiovascular subjects diabetes.
Subjects:JOURNALS
ID Code:7317
Deposited By:CurrentSciDirect Publications, International Journal of Current Biological and Medical Science (IJCBMS)
Deposited On:02 May 2011 16:52
Last Modified:02 May 2011 16:52

References in Article

Select the SEEK icon to attempt to find the referenced article. If it does not appear to be in cogprints you will be forwarded to the paracite service. Poorly formated references will probably not work.

[1] Shen R, Wiegers SE, Glaser R. The evaluation of cardiac and peripheral arterial disease in patients with diabetes mellitus. Endocr Res. 2007;32:109-142.

[2] Wu JT, Wu LL. Linking inflammation and atherogenesis: Soluble markers identified for the detection of risk factors and for early risk assessment. Clin Chim Acta .2006;366:74-80.

[3] Vitale C , Fini M, Leonardo F, Rossini P, Cerquetani E, Onorati D . Effect of estradiol valerate alone or in association with cyproterone acetate upon vascular function of postmenopausal women at increased risk for cardiovascular disease, Maturitas. 2001;40:239–245.

[4] Farah R, Shurtz-Swirski R, Lapin O. Intensification of oxidative stress and inflammation in type II diabetes despite antihyperglycemic treatment. Cardiovasc Diabetol. 2008;7:1-8.

[5] de Rekeneire N, Peila R, Ding J, Colbert L H, Visser M, Shorr R I. Diabetes, hyperglycemia, and inflammation in older individuals: the health, aging and body composition study. Diabetes Care. 2006;29:1902-1908.

[6] Leitinger N. Oxidized phospholipids as modulators of inflammation in atherosclerosis. Curr Opin Lipidol 2003;14:421-430.

[7] Petitti DB, Imperatore G, Palla SL, Daniels SR, Dolan LM, Kershnar AK. Serum lipids and glucose control: the search for diabetes in youth study. Arch Pediatr Adolesc Med .2007;161 : 159 –165.

[8] Abdel-Gayoum AG. The effect of glycemic control in type II diabetic patients with diabetes-related dyslipidemia. Saudi Med J. 2004;25:207-211.

[9] Meisinger C, Lowel H, Heier M, Schneider A, Thorand B. KORA Study Group. Serum gamma-glutamyltransferase and risk of type 2 diabetes mellitus in men and women from the general population. J Intern Med. 2005;258:527-535.

[10] Dehghan A, Hoek M, Sijbrands EJ, Stijnen T, Hofman A, Witteman JC. Risk of type 2 diabetes attributable to C-reactive protein and other risk factors. Diabetes Care. 2007;30:2695-2699.

[11]Esper RJ, Vilariño JO, Machado RA, Paragano A. Endothelial dysfunction in normal and abnormal glucose metabolism. Adv Cardiol .2008;45:17-43.

[12] Simão AN, Dichi JB, Barbosa DS, Cecchini R, Dichi I . Influence of uric acid and gamma-glutamyltransferase on total antioxidant capacity and oxidative stress in patients with metabolic syndrome. Nutrition. 2008;24:675-81.

[13] Sedda V, Chaira BD, Parolini M, Caruso R, Campolo J, Cighetti G. Plasma glutathione level are independently associated with Gamma Glutamyl transferase activity in subjects with cardiovascular risk factors. Free Rad Res. 2008;42:135-141.

[14] Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev. 2007;87:315-424.

[15] Roberts WL, Sedrick R, Moulton L, Spencer A, Rifai N. Evaluation of four automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Clin Chem. 2000;46:461-468.

[16] Schumann G, Bonora R, Ceriotti F, Clerc-Renaud, P, Ferard G, Ferrero CA. IFCC primary reference procedures for the measurement of catalytic activity concentrations of enzymes at 37o C. Part 6, Reference procedure for the measurement of catalytic concentration of gamma glutamyltransferase. Clin Chem Lab Med. 2002;40:734-738.

[17] Giovannoni G, Land JM, Keir G, Thompsion EJ, Heales SJR. Adaption of nitric reductase and Griess reaction methods for measurement of serum nitrate plus nitrite levels. Ann Clin Biochem. 1997; 34:193-198.

[18] Goldstein DE, Little RR, Wiedmeyer HM, England JD, Rohlfing CG. Glycated haemoglobin estimation in the 1990’s: A review of assay methods and clinical interpretation. In: Marshall SM, Home PD, editor. The Diabetes Annual. New York (NY): Elsevier Science B.V.1994;1:193–212.

[19] Ellerbe P, Myers GL, Cooper GR, Hert HS, Sniegoski LT, Welch MJ. A comparison of results for cholesterol in human serum by the reference method and by the definitive method of the National Reference System for cholesterol. Clin Chem. 1990;36: 370-375.

[20] Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med .2004;141:421-431.

[21] Middelbeek RJ, Horton ES. The role of glucose as an independent cardiovascular risk factor. Curr Diab Rep. 2007;7:43-49.

[22]Schulze MB. Rimm EB, Li T, Rifai N, Stampfer MJ, Hu FB. C-reactive protein and incident cardiovascular events among men with diabetes. Diabetes Care. 2004;27:889–894.

[23]Pereira FO, Frode TS, Medeiros YS. Evaluation of tumour necrosis factor alpha, interleukin-2 soluble receptor, nitric oxide metabolites, and lipids as inflammatory markers in type II diabetes mellitus. Mediators Inflamm. 2006;1:1-7.

[24] Pfutzner A, Forst T. High-sensitivity C - reactive protein as Cardiovascular risk marker in patients with diabetes mellitus. Diabetes Technol Ther .2006;8:28-36.

[25] Ridker PM. C-reactive protein: eighty years from discovery to emergence as a major risk marker for cardiovascular disease. Clin Chem .2009; 55: 209–215.

[26] Marsik C, Kazemi-Shirazi L, Schickbauer T, Winkler S, Wagner OF, Endler G. C-reactive protein and all-cause mortality in a large hospital-based cohort. Clin Chem .2008;54:234-237.

[27] Izumi N, Nagaoka T, Mori F, Sato E, Takahashi A, Yoshida A. Relation between plasma nitric oxide levels and diabetic retinopathy. Jpn J Ophthalmol. 2006;50:465-468.

[28] Ramakrishna V, Jailkhani R. Oxidative stress in non-insulin-dependent diabetes mellitus (NIDDM) patients. Acta Diabetol .2008;45:41-46.

[29]Bauersachs J, Schaefer A. Tetrahydrobiopterin and eNOS dimer/monomer ratio: a clue to eNOS uncoupling in diabetes? Cardiovasc Res .2005;65:823-831.

[30]Guzik TJ, Mussa S, Gastaldi D, Sadowski J, Ratnatunga C, Pillai R.Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation. 2002;105:1656–1662.

[31]Verma S, Wang CH, Li SH, Dumont AS, Fedak PW, Badiwala MV. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation .2002; 106:913-919.

[32] Lee MY, Koh SB, Koh JH, Nam SM, Shin JY, Shin YG. Relationship between gamma-glutamyltransferase and metabolic syndrome in a Korean population. Diabet Med .2008;25:469-475.

[33] Lee DS, Evans JC, Robins SJ, Wilson PW, Albano I, Fox CS. Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: The Framingham Heart Study. Arterioscler Thromb Vasc Biol. 2007;27:127–133.

[34] Bradley RF, Marble A, White P, Krall LP. Cardiovascular disease. In: Marble A, ed. Joslin's Diabetes Mellitus. Philadelphia, Pa: Lea & Febiger. 1971:417-425.

[35] Devine SM, Liedtke AJ, Zelis R. Coronary artery disease in diabetic patients. In: Scott R, ed. Clinical Cardiology and Diabetes, vol. II. Mt Kisco, NY: Futura Publishing Co.1981:1-87.

[36] Garcia MJ, Gordon T, McNamara PM, Kannel WB. Morbidity and mortality in diabetics in a general population: sixteen year follow-up experience in the Framingham study. Diabetes. 1974;23:105-111.

[37] Scott RC. Diabetes and the heart. Am Heart J. 1975;90:283-289.

[38] Root HF, Bland EF, Gordon WH, White PD. Coronary atherosclerosis in diabetes mellitus: a post-mortem study. JAMA. 1939;113:27-31.

[39] Dortimer AC, Shenoy PN, Shiroff RA, Leaman DM, Babb JB, Liedtke AJ, Zelis R. Diffuse coronary artery disease in diabetic patients: fact or fiction?. Circulation. 1978; 57:133-136.

Metadata

Repository Staff Only: item control page